Purpose of review Spontaneous remyelination occurs in the central nervous system of patients with multiple sclerosis. However, this process is not robust enough to promote a functional and stable recovery of the myelin architecture. The development of cellbased therapies, aimed at promoting multifocal remyelination, is therefore foreseen. Recent findings Several experimental cell-based strategies aimed at replacing damaged myelin-forming cells have been developed in the last few years. However, most of these therapeutic approachesalthough consistently able to form new myelin sheaths at the transplantation site -are unfeasible owing to the mutifocality of the demyelinating process in multiple sclerosis patients and the inability to grow and produce large numbers of differentiated myelin-forming cells in vitro. Stem cell-based therapies that partially overcome these limitations have been proposed recently. Summary Stem cell-based remyelinating therapies can be considered a plausible alternative strategy in immune-mediated demyelinating disorders. However, before any potential applications in patients with multiple sclerosis can be envisaged, it is necessary to confront the following preliminary, and still unsolved, questions: (1) the ideal stem cell source for transplantation; (2) the most appropriate route of stem cell administration; and, last but not least, (3) the best approach for achieving an appropriate, functional and long-lasting integration of transplanted stem cells into the host tissue. 
Introduction
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS), whose aetiology remains unknown. MS pathology is characterized by the presence, within the CNS, of perivascular lympho/mononuclear inflammatory infiltrates inducing, over the years, patchy demyelination, axonal loss and reactive astroglial scarring [1, 2] . In this context, spontaneous remyelination -the process by which endogenous oligodendrocyte progenitor cells (OPCs) re-ensheath demyelinated axons -occurs and some axons may recover their capacity to conduct action potentials [3] [4] [5] [6] . However, spontaneous remyelination fails over time in MS, and the unavoidable progression of demyelination and axonal damage invariably leads to permanent neurological deficits [7, 8] .
Spontaneous remyelination occurs in patients with multiple sclerosis
The adult CNS is known to be somehow reactive to tissue injuries (i.e. those that are ischaemic, toxic, traumatic, etc.) including those causing immunemediated demyelination and axonal loss. Studies in humans as well as in rodents have demonstrated that both in MS as well as in its experimental animal modelnamely experimental autoimmune encephalomyelitis (EAE) -spontaneous myelin repair may occur as a physiological response to the immune-mediated destruction of the myelin sheath [9, 10 . ]. It is still debated as to which type of cell drives axon re-ensheathment in vivo. In remyelinated areas, terminally differentiated oligodendrocytes as well as stellate-shaped (either NG2-positive or O4-positive) OPCs have been found [9, 10 . , [11] [12] [13] . However, OPCs -expressing the receptor for platelet-derived growth factor-a or the proteoglycan NG2 -are more efficient than post-mitotic oligodendrocytes in sustaining the anatomical and functional restoration of myelin integrity, as indicated by experiments involving transplantation into chemically demyelinated rat spinal cord white-matter areas [14] [15] [16] . Whatever the cell driving axon re-ensheathment in vivo, the process of functional remyelination is often incomplete and limited in MS. Although the ultimate reason why spontaneous remyelination fails over time in MS remains unknown, some explanations can be put forward. In an elegant review by Franklin [8] , the most likely causes of remyelination failure in MS are summarized, as follows: (1) loss of OPCs as well as a scarce ability of these cells to differentiate and remyelinate injured axons; (2) failure of OPCs to 'respond' to demyelination; (3) selective depletion of myelinating cells around demyelinating areas over years; (4) inhibition of remyelination as result of a 'delicate' balance between pro-inflammatory and pro-remyelinating effects of cytokines; (5) limitation of endogenous OPC migration to sites of injury by reactive astrocytic scar formation; and (6) acute and/or chronic loss of axons.
Different sources of myelin-forming cells for central nervous system remyelinating approaches
Since the early 1970s, several transplantation procedures aimed at restoring the myelin architecture within CNS demyelinated areas have been developed (Table 1 [ [43] . In particular, lineage-restricted myelinogenic cells show limited growth and expansion characteristics in vitro [44, 45] and, once transplanted (in vivo), induce remyelination only within restricted CNS areas close to the transplantation site [43, 46] .
Mature oligodendrocyte and oligodendrocyte progenitor cells
Post-mitotic oligodendrocytes as well as OPCs have been widely used to promote remyelination in rodent models of focal CNS demyelination. When focally injected within the site of chemically induced (i.e. using ethidium bromide) myelin damage, cultured oligodendrocytes showed a poor remyelination capacity [17] [18] [19] , whereas OPCs displayed greater mitotic, migratory and reparative properties [20, 21, 47] . Interestingly, transplanted OPCs seem to be more efficient than endogenous OPCs in repairing the myelin sheath [48] . Very recently, A2B5 + /poly-syalilated-neural cell adhesion molecule (PSA-NCAM) 7 enriched OPCs have been extracted from either foetal human forebrain or adult human brain white matter and then xenografted intracallosally to the forebrain of newborn mice affected by genetically determined myelinopathy (e.g. shiverer, shi/shi). Both OPC populations were found dispersed throughout the brain white matter, differentiated into oligodendrocytes and remyelinated nude axons; the adult OPCs myelinating the shi/shi brain more rapidly (i.e. in 4 weeks as opposed to 12 weeks) and efficiently than the foetal counterpart [22 . ].
Schwann cells
The well-established ability of Schwann cells to myelinate CNS demyelinated areas [23] has fostered the wide use of these cells as an alternative cell source to drive exogenous remyelination [43] . The use of neural stem cells in remyelinating therapies
As previously discussed, the intrinsically complex nature of MS -in particular its chronicity and multifocality -poses great challenges for cell-based remyelinating therapies. Two major requirements have to be satisfied: there must be (1) an unlimited source of cells, and (2) the possibility of accessing several damaged areas of the CNS at the same time. As we discuss in detail later on, the functional and morphological properties of uncommitted neural precursors, such as neural stem cells (NSCs), might be envisaged as providing a promising alternative for transplantation approaches in MS. However, there are some preliminary questions that need to be solved before the prospecting of any potential human application of such therapies: (1) the ideal stem cell source for transplantation; (2) the route of cell administration; and (3) the differentiation and persistence of cells transplanted into the targeted tissue. Last, but not least, functional and long-lasting integration of transplanted cells into the host tissue has to be achieved.
The cell source
Whatever the organ or tissue necessities, the 'gold standard' cell for replacement therapies has to be inherently plastic. Stem cells can fulfil this criterion since they are intrinsically able to adapt their cell fate to different environmental needs. Both embryonic stem cells and adult neural stem cells (aNSCs) might represent the ideal cell source for cell replacementbased therapies in CNS disorders. Embryonic stem cellderived neural progenitors, although representing a promising source of NSCs, have not been consistently used for transplantation purposes so far [50, 51] .
Embryonic stem cells
Embryonic stem cells, derived from the inner cell mass of blastocyst-stage embryos, are totipotent cells able to give rise to a differentiated progeny representative of all three embryonic germ layers as well as of the extraembryonic tissues supporting development. Embryonic stem cell lines can actually be established from virtually all mammals [52, 53] . In humans, blastocysts for the establishment of renewable human embryonic stem cell lines can actually be obtained from either supernumerary embryos (from in-vitro fertilization procedures) or from embryos specifically created for research purposes (i.e. nuclear transfer, parthenogenetic activation of the egg) [54] [55] [56] 57 . . ]. Embryonic stem cells can be propagated (under certain in-vitro conditions) almost indefinitely, with maintenance of a normal karyotype and totipotency, as was recently shown by the culturing of embryonic stem cell lines in the presence of leukaemia inhibitory Used to indicate genetically heterogeneous outbred mice, which are usually developed by crossing inbred strains (i.e. A, AKR, BALB/c, C3H/2, C57BL, DBA/2, Is/Bi, and RIII) and maintained by random mating of families, avoiding common grandparents for several (i.e. 450-60) generations.
factor [58] . Embryonic stem cells can be also induced to differentiate in vitro in almost all cell types of the body [59] [60] [61] , including neural cells, which can be obtained by supplying cells with growth factors such as epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor-2 [31, 62, 63] . When transplanted in rodent models of either genetically determined or chemically induced demyelination (both within the brain and the spinal cord), embryonic stem cells have been able to differentiate into glial cells and re-ensheath demyelinated axons in vivo [31] [32] [33] . However, most of the recent experimental transplantation studies involving embryonic stem cells have been complicated by the formation of heterologous tissues and teratomas within the organ of transplantation [34, 64, 65] , thus suggesting that, at least in certain circumstances, the cross-talk between transplanted pluripotent embryonic stem cells and the tissue of transplantation might not adequately control ES cell differentiation. To overcome such limitations, at least partially, protocols for generating, in vitro, high numbers of cell type-specific neural precursors (e.g. oligodendroglial lineage cells) from embryonic stem cells have been recently developed [50, 51] .
Adult neural stem cells
Mammalian aNSCs support neurogenesis and gliogenesis within restricted areas of the CNS throughout adulthood, can undergo extensive in-vitro expansion upon epigenetic stimulation, and possess the capacity to generate a progeny of neural cells which can integrate into, and repair, the tissue of origin [66, 67] . These cells can be isolated from foetal as well as adult brains and can be expanded and maintained safely in a chemically defined medium for years, thus supporting the concept that these uncommitted NSCs might represent a renewable source of cells that can be used for transplantation procedures [68, 69 . . ]. These cells, in fact, show: (1) growth factor-dependent proliferation and a stable growth rate; (2) a capacity for self-renewal; (3) multipotentiality; and (4) functional plasticity either over serial in-vitro passaging or after several freezing-thawing cycles [70, 71] . Furthermore, aNSC plasticity and functional flexibility can be modulated in vitro by exposure to different growth factors [66] . As an example, leukaemia inhibitory factor, brain-derived neurotrophic factor, ciliary neurotrophic factor, neurotrophin-3, and neurotrophin-4 drive aNSCs towards a neuronal fate (up to 40-60% of cells in culture), whereas bone-morphogenetic proteins, ciliary neurotrophic factor and leukaemia inhibitory factor increase the number of aNSC-derived astrocytes [72, 73] .
In-vivo experiments designed to repair a demyelinated CNS by the transplanting of multipotent aNSCs have shown that these cells might survive within the host CNS, display notable migratory properties from the site of grafting, and maintain their multipotency [35] . In experimental autoimmune, chemical or traumatic CNS demyelination, aNSCs -transplanted intraparenchymally, intracerebroventricularly or intravenously -show the ability to selectively reach the areas of tissue damage, to differentiate into axon-ensheathing oligodendrocytes, and to promote functional recovery [36, 37, 38 . ,39 . . ,40 . ,
]. Notably, aNSC transplants, in both healthy and diseased rodents, have not induced tumour formation, thus strongly suggesting that the tumorigenic potential in vivo of such a potent cell source is minimal.
The route of cell administration
The route of cell administration represents another key issue for NSC transplantation procedures in multifocal CNS diseases. On the one hand, the anatomo-pathological features of focal CNS disorders, such as Parkinson's disease or spinal cord injuries, would suggest that direct intralesional cell transplantation might facilitate tissue regeneration within a specific area of the CNS. On the other hand, the challenge posed by the mutifocality of certain CNS disorders, such as MS, would, per se, limit the feasibility of certain cell replacement-based therapies. However, some recent experiments have shown that, at least, in multifocal inflammatory brain disorders these limitations can be overcome by injecting therapeutic cells (e.g. bone marrow cells, mesenchymal cells, aNSCs) into the blood stream (intravenously) or into the cerebrospinal fluid circulation (intracerebroventricularly). Once intravenously or intracerebroventricularly injected, these cells travel along these two bodily fluids and reach multiple inflamed areas of both the brain and the spinal cord. This specific homing has been explained, at least in part, by the constitutive expression by transplanted stem cells of a wide array of inflammatory molecules such as adhesion molecules (i. Ideally, once in the target organ, therapeutic stem cells should differentiate into the appropriate daughter cells and persist as long as needed at the site of engraftment. However, although very little is known about the mechanisms instructing the terminal differentiation of stem cells in vivo, there is strong evidence that the local environment might dictate the fate of transplanted uncommitted stem cells. In this respect, undifferentiated multipotent aNSCs or even totipotent embryonic stem cells, transplanted in different experimental neurological conditions, have shown a considerable capacity to restrict their fate to tissue-specific cues and replace nonfunctioning neural cells of different lineages.
Totipotent embryonic stem cells display a preferential terminal differentiation into myelinating oligodendrocytes when transplanted into rodents affected by experimental acute spinal cord injury [31] [32] [33] . Even more efficiently, multipotent growth factor-responsive aNSCs have shown glial lineage-restricted fate when transplanted in animal models of myelin dysfunction (e.g. EAE, spinal cord injury) [36, 37, 38 . ,39
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. ]. Thus, the local environment may dictate the fate of transplanted pluripotent or multipotent stem cells. However, transplanted stem cells might exert their therapeutic effect not only by differentiating into lineage-restricted daughter cells and by functionally integrating into the host tissue. It has been recently shown that upon transplantation -no matter what the characteristics of the CNS injured area into which cells have been transplanted -aNSCs might remain in an undifferentiated state (e.g. lacking antigens of differentiation, having a round morphology, and having perivascular localization) but continue to release neuroprotective growth factors (fibroblast growth factor-2, brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, etc.) [38 . ,39 . . ,91 . ]. This latter evidence might suggest that aNSC-dependent brain repair may also be due to a 'bystander' activity of stem cells modulating the rescue of neurons and/or oligodendrocytes via both the constitutive or environmentinduced release of neurotrophic molecules and the inhibition of myelin-reactive encephalitogenic T-cell proliferation [40 . ].
Functional integration
The functional integration of stem cells at the site of homing/transplantation is the most critical issue. Although indications that stem cells can reach the target organ and differentiate into the appropriate lineage exist, there is still scarce evidence that these cells can reconstruct the three-dimensional brain architecture and give rise to properly functioning cells integrating into the brain circuitries. Further studies fulfilling several strict criteria are therefore necessary to determine whether a stem cell has generated a functional neuronal or glial cell. So far, most studies on NSCs have relied strictly on morphological or immunohistochemical evidence. . ]. Moreover, bone marrow-derived stromal cells from green fluorescent protein-expressing mice (immunoreactive for collagen type I, fibronectin, and CD44) determined remyelination and improvement of axonal conduction velocity once transplanted by direct microinjection into the demyelinated spinal cord of immunosuppressed rats [42] . Together, these findings support the concept that BMSCs might be useful as a therapeutic tool for brain repair. However, despite this experimental and human evidence, the actual therapeutic contribution of BMSC transplantation in brain pathologies remains controversial [93, 94 . . This is an interesting paper describing the dynamics of rat neural precursor cells once intracerebroventricularly transplanted into EAE rats. Cells transplanted at the peak of EAE migrated exclusively into inflamed white-matter areas of the brain and spinal cord parenchyma and acquired specific markers of the astroglial and oligodendroglial lineages. This study shows that neural precursor cells might protect against EAE development -once intraventricularly transplanted -via the inhibition of the proliferation of myelin-reactive encephalitogenic T cells.
